Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ablynx : files for $150M IPO to build on phase 3 boost

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:11pm CET

Ablynx has moved quickly to capitalize on the boost to its prominence and prospects provided by recent phase 3 data. The Belgian biotech has joined the reopened path from Europe to Wall Street in pursuit of $150 million (128 million) to support its commercialization and clinical trial activities.

Caplacizumab is the centerpiece of the post-IPO spending plans. With top-line phase 3 data posted this week linking caplacizumab to a statistically significant drop in time to platelet count response, Ablynx is gearing up to commercialize the anti-von Willebrand factor single-domain antibody in the U.S. and Europe. The IPO will support this work by giving Ablynx cash to invest in sales, marketing and distribution infrastructure.

ALX-0171 is the most important drug affected by the IPO from an R&D perspective. Ablynx plans to use the funds to move the wholly owned treatment for respiratory syncytial virus (RSV) through a phase 2b trial.

That 180-patient trial got underway at the start of the year and is due to wrap up in the back half of next year, potentially providing IPO investors with a shot at an early boost to the value of their holdings. Ablynx plans to seek a partner for ALX-0171 after the phase 2b data to help it test it the nebulized drug in phase 3 in infants hospitalized by RSV. The Belgian biotech is also looking to the anticipated partnership to support exploration of the use of ALX-0171 in primary healthcare.

ALX-0171 is unlikely to dictate the success of the IPO, though. Investors will be paying the most attention to caplacizumab, specifically whether the statistical success in phase 3 indicates the drug has the risk-benefit profile needed to establish itself in the acquired thrombotic thrombocytopenic purpura (aTTP) treatment pathway.

This analysis centers on whether the clinical significance of the reduced time to platelet response outweighs the adverse events linked to caplacizumab, most notably bleeding. Ablynxs graph of the percentage of patients in both arms shows many subjects on placebo improved at a similar speed to those on caplacizumab. However, in its favor, Ablynx has data linking caplacizumab to a drop in the recurrence of aTTP.

The data proved compelling enough to drive Ablynxs stock up more than 20% in Europe, where it has traded publicly since 2007. Ablynx is making shares available to investors on its home continent through a private placement it is performing in parallel to the Nasdaq IPO.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
12/12 ABLYNX : 12/12/2017 ablynx reports additional clinically important benefits of c..
12/12 ABLYNX : Reports additional clinically important benefits of caplacizumab from i..
12/07 ABLYNX : Will host a webcast to discuss additional data from its phase iii hercu..
11/29 ABLYNX : 29/11/2017 publication in accordance with article 14 of the belgian law..
11/29 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/21 ABLYNX : 21/11/2017 results from the phase iii hercules study of caplacizumab fo..
11/21 ABLYNX : Results from the phase iii hercules study of caplacizumab for the treat..
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
More news
News from SeekingAlpha
12/07 Ablynx to update on Phase 3 study of caplacizumab December 12
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,2 M
Net income 2017 -73,4 M
Finance 2017 203 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,6x
EV / Sales 2018 23,8x
Capitalization 1 536 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 22,9 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX87.52%1 805
CELLTRION, INC.--.--%23 756
IQVIA HOLDINGS INC34.41%21 227
INCYTE CORPORATION-2.16%20 346
LONZA GROUP62.09%19 523
ALNYLAM PHARMACEUTICALS, INC.233.49%12 349